Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.

Petra El KhouryRonan RousselFrederic FumeronYara Abou-KhalilGilberto VelhoKamel MohammediMarie-Paule JacobPhilippe Gabriel StegLouis PotierYoumna GhalebSandy ElbitarStephanie RagotFrancesco AndreataGiusepinna CaligiuriSamy HadjadjCatherine BoileauMichel MarreMarianne AbifadelMathilde VarretBoris Hansel

Published in: Diabetes, obesity & metabolism (2018)

We found that PCSK9 was inconsistently associated with CV events in populations with type 2 diabetes. The association may depend on the level of CV risk and the background treatment.

Keyphrases

cardiovascular events
low density lipoprotein
type diabetes
cardiovascular disease
coronary artery disease
glycemic control
insulin resistance
metabolic syndrome
combination therapy
genetic diversity